| Outcome Measures: |
Primary: Baseline-adjusted iGFR at 8 weeks after randomization, GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its baseline value, 8 weeks after randomization|Baseline-adjusted iGFR at the end of the drug wash-out period, GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its baseline value, 84 weeks after randomization|Baseline-adjusted levels of serum biomarkers of increased ESKD risk at the end of the drug wash-out period, Levels of the following 21 serum biomarkers, adjusted by their baseline values: CD160, CD27, DLL1, EDA2R, EFNA4, EPHA2, GFRA1, IL1RT1, KIM1, LAYN, LTBR, PI3, PVRL4, RELT, SYND1, TNFR1, TNFR2, TNFRSF10A, TNFRSF4, TNFRSF6B, WFDC2, 84 weeks after randomization | Secondary: Baseline-adjusted iGFR at the end of treatment, GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its baseline value, 76 weeks after randomization|iGFR at the end of treatment, GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its value at week 8, 76 weeks after randomization|Baseline-adjusted eGFR-SCr at 8 weeks after randomization, GFR estimated from serum creatinine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value, 8 weeks after randomization|Baseline-adjusted eGFR-SCr at the end of treatment, GFR estimated from serum creatinine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value, 76 weeks after randomization|eGFR-SCr at the end of treatment, GFR estimated from serum creatinine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its value at week 8, 76 weeks after randomization|Baseline-adjusted eGFR-SCr at the end of the wash-out period, GFR estimated from serum creatinine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value, 84 weeks after randomization|Baseline-adjusted eGFR-CysC at 8 weeks after randomization, GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value, 8 weeks after randomization|Baseline-adjusted eGFR-CysC at the end of treatment, GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value, 76 weeks after randomization|eGFR-CysC at the end of treatment, GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its value at week 8, 76 weeks after randomization|Baseline-adjusted eGFR-CysC at the end of the wash-out period, GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value, 84 weeks after randomization|Baseline-adjusted uAER at 8 weeks after randomization, Urinary Albumin excretion rate (uAER, mg/24/hr) based on overnight urine collection, adjusted by its baseline value, 8 weeks after randomization|Baseline-adjusted uAER at the end of treatment, Urinary albumin excretion rate (uAER, mg/24 hr) based on overnight urine collection, adjusted by its baseline value, 76 weeks after randomization|uAER at the end of treatment, Urinary Albumin excretion rate (uAER, mg/24 hr) based on overnight urine collection, adjusted by its value at week 8, 76 weeks after randomization|Baseline-adjusted uAER at the end of the wash-out period, Urinary albumin excretion rate (uAER, mg/24 hr) based on overnight urine collection, adjusted by its baseline value, 84 weeks after randomization|Baseline-adjusted creatinine clearance at 8 weeks after randomization, Creatinine clearance (ml/min) based on overnight urine collection, adjusted by its baseline value, 8 weeks after randomization|Baseline-adjusted ERPF at 8 weeks after randomization, Effective renal plasma flow (ml/min) measured by means of para-aminohippurate infusion, adjusted by its baseline value, 8 weeks after randomization|Baseline-adjusted afferent renal arteriolar resistance at 8 weeks after randomization, Afferent renal arteriolar resistance (dyne/s/cm5) measured by means of para-aminohippurate infusion, adjusted by its baseline value, 8 weeks after randomization|Baseline-adjusted efferent renal arteriolar resistance at 8 weeks after randomization, Efferent renal arteriolar resistance (dyne/s/cm5) measured by means of para-aminohippurate infusion, adjusted by its baseline value, 8 weeks after randomization|Baseline-adjusted glomerular hydrostatic pressure at 8 weeks after randomization, Glomerular hydrostatic pressure (mmHg) measured by means of para-aminohippurate infusion, adjusted by its baseline value, 8 weeks after randomization|Baseline-adjusted glomerular filtration pressure at 8 weeks after randomization, Glomerular filtration pressure (mmHg) measured by means of para-aminohippurate infusion, adjusted by its baseline value, 8 weeks after randomization|Baseline-adjusted glomerular oncotic pressure at 8 weeks after randomization, Glomerular oncotic pressure (mmHg) measured by means of para-aminohippurate infusion, adjusted by its baseline value, 8 weeks after randomization|eGFR-SCr trajectory, Trajectory of GFR estimated from serum creatinine (ml/min/year/1.73 m2) using the CKD-EPI equation, 8 to 76 weeks from randomization|eGFR-SCys trajectory, Trajectory of GFR estimated from serum cystatin C (ml/min/year/1.73 m2) using the CKD-EPI equation, 8 to 76 weeks from randomization|Baseline-adjusted levels of serum biomarkers of increased ESKD risk at the end of treatment, Levels of the following 21 serum biomarkers, adjusted by their baseline values: CD160, CD27, DLL1, EDA2R, EFNA4, EPHA2, GFRA1, IL1RT1, KIM1, LAYN, LTBR, PI3, PVRL4, RELT, SYND1, TNFR1, TNFR2, TNFRSF10A, TNFRSF4, TNFRSF6B, WFDC2, 76 weeks after randomization|Levels of serum biomarkers of increased ESKD risk at the end of treatment, Levels of the following 21 serum biomarkers, adjusted by their values at week 8: CD160, CD27, DLL1, EDA2R, EFNA4, EPHA2, GFRA1, IL1RT1, KIM1, LAYN, LTBR, PI3, PVRL4, RELT, SYND1, TNFR1, TNFR2, TNFRSF10A, TNFRSF4, TNFRSF6B, WFDC2, 76 weeks after randomization
|
